Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2770604 | Revue Française d'Allergologie et d'Immunologie Clinique | 2006 | 4 Pages |
Abstract
The hypereosinophilic syndrome, and asthma and other allergic diseases are characterized by a proliferation and/or activation of polynuclear eosinophils, the production, maturation and activation of which are mediated by interleukin-5 (IL-%). In recent years, several preparations having anti-IL5 activity, aimed at regulating the activity of eosinophils, have been developed and evaluated. Still, there have been few clinical studies. Two molecules, STI-571 and SB-240563 have been found to have interesting results in phase I/II studies in the hypereosinophilic syndrome, with amelioration of clinical and biological parameters. One phase III study of SB-240563 in this condition is presently underway. In asthma, in spite of a significant reduction of infiltration of eosinophils in the blood and tissues, no molecule has as yet shown clinical benefit.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
S. Pouwels-Fry, B. Wallaert,